Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/160558
Title: Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
Author: Laguno Centeno, Montserrat
Von Wichmann, M. A.
van den Eynde, Eva
Navarro, J.
Cifuentes, C.
Murillas Angoiti, Javier
Veloso, Sergio
Martínez Rebollar, María
Guardiola, J. M.
Jou , A.
Gómez-Sirvent, J. L.
Cervantes, M.
Pineda, J. A.
López-Calvo, S.
Carrero, A.
Montes, María Luisa
Deig, E.
Tapiz, A.
Ruiz-Mesa, J. D
Cruceta, A.
de Lazzari, E.
Mallolas Masferrer, Josep
Keywords: Hepatitis C
Interferó
Espanya
Hepatitis C
Interferon
Spain
Issue Date: 1-Nov-2016
Publisher: Elsevier B.V.
Abstract: Introduction Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferon-free therapies are not available yet.
Note: Versió postprint del document publicat a: https://doi.org/10.1016/j.ijid.2016.10.028
It is part of: International Journal Of Infectious Diseases, 2016, num. 53, p. 46-51
URI: http://hdl.handle.net/2445/160558
Related resource: https://doi.org/10.1016/j.ijid.2016.10.028
ISSN: 1201-9712
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
672796.pdf559.6 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons